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With the rapid progression of biotechnologies in the last few
decades, molecular biology assays have shifted from limited to
high throughput. Indeed, we successively witnessed an accelerated
development of ‘omics technologies at multiple molecular scales:
DNA arrays, DNA methylation screening, proteome-wide interac-
tion screening, Chip-Seq, protein array, next generation sequenc-
ing, RNA-seq and next generation protein mass-spectrometry.
The availability of large repository of ‘omics data has stimulated
the proliﬁc growth of analytical methods for clinical outcome pre-
diction specialized for one type of ‘omics measurement, but com-
paratively fewer cross-scales ones (2 molecular scales) and very
rare multiple scales ones (P3 molecular scales; ‘‘multiscale’’). Of
note, abundant original cross-scale and multiscale ‘omics methods
have been developed for identifying gene function [1], novel dis-
ease-gene [2,3] and diseases’ biomodules (e.g. biomodules of micr-
oRNA-mRNA co-expression [4]). However, these approaches are
insufﬁcient for predicting clinical outcome of complex disorders
[5,6]. Here, we provide a framework to illustrate the difﬁculty of
increasing the accuracy of a clinical outcome predictor from multi-
ple scales of ‘omics data, and position the signiﬁcance of Kim et al.
[7] that appears in this issue of the Journal of Biomedical Informat-
ics. We also include a brief historical perspective of foundational
methodologies in cross-scale and multiscale ‘omics analytics (sin-
gle ‘omics analytics are out of scope of this perspective).1 The number of mathematical models required to specify each interaction
between n scales of ‘omics measurements increases as follows (note that combina-
tions of higher order than binary are included, e.g. ternary, quaternary, etc.):
Count of Interaction Models ¼ ð2n  n 1Þ:2. Categorization of cross-scale and multiscale analytics
Through complementary or synergistic information between
two genome-wide ‘omics measures, the ﬁnest methodological
developments in cross-scale analyses magnify the accuracy of dis-
covery science and their statistical power on smaller samples size.
Furthermore, while cross-scales studies employ linear as well as
complex non-linear analytical mathematics, multiscale ones have
generally been deceivingly simple in terms of modeling, proposing
one integrative approach regardless of the biomedical scale. In-
deed, the complexity of independently modeling each combination1532-0464/$ - see front matter  2012 Elsevier Inc. All rights reserved.
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integration of n scales has not yet been attempted. Combinatorics
informs us that such modeling grows exponentially with scale.1
Fig. 1 provides a timeline (x axis) of pioneering cross-scale (2
scales) and multiscale (P3 scales) ‘omics studies for predicting
clinical outcome. Cross-scales clinical outcome predictors from
‘omics data precede the more complex multiscale ones; integration
of fewer ‘omics scales (Fig. 1, small size shapes) also precedes inte-
gration of more scales (Fig. 1, large size shapes). The y-axis of Fig. 1
represents the difﬁculty of the prediction: diagnosis, followed by
prognosis and response to therapy. Evidently, seminal studies per-
taining to simpler problems (y axis, near origin) precede those
addressing more difﬁcult ones (y axis, away from the origin). Fur-
ther, predicting the outcome using a continuous clinical variable
(regression-type problem; e.g. survival; Fig. 1, green2) is harder
than with ordinal variables (light green; e.g. cancer stage) or a qual-
itative one (Fig. 1, yellow; cancer subtypes). Two forms of data inte-
gration are observed in these studies of clinical outcome prediction:
(i) the earlier studies corroborate a single scale predictor with an-
other scale (Fig. 1, triangles), then followed by (ii) more complex
data fusion (Fig. 1, circles), deﬁned as ‘‘the process of integration of
multiple data and knowledge representing the same real-world ob-
ject into a consistent, accurate, and useful representation’’.3 Corrob-
orative ‘omics studies have preceded deeper mathematical
integration and data fusion for each type of biological problem (y axis).3. Predicting clinical outcome of complex disorders
Mendelian disorders can be diagnosed with a single genetic
marker that also provides insight in the underpinning biological
mechanisms. Predicting clinical outcome of complex diseases has
conventionally leveraged this principle using single molecularThus, for n = 3,4, 5 or 6 scales, the number of interaction models required are 4, 11, 26, or
57, respectively.
2 For interpretation of color in Fig. 1, the reader is referred to the web version of
this article.
3 http://en.wikipedia.org/wiki/Data_fusion.
Fig. 1. Seminal integrative genomics analytics leading to predicting increasingly difﬁcult clinical outcome problems. Nine seminal methodological studies that led to the use
of data fusion across four scales of ‘omics data are presented in a timeline (x axis) according to four additional characteristics: the increasing difﬁculty of the clinical
prediction (y axis), the level of data integration (shape), the number of ‘omics scales integrated (size), the complexity of the clinical variable to predict (color). Full integration
or fusion of biological data (circles) has, in principle, more predictive accuracy than corroboration between scales (triangles). However, the former are more complex and are
discovered later historically (circles follow triangles). Kim’s method classiﬁes clinical prognosis by fusing four ‘omics scales, and shows that comprehensive multiscale fusion
is more accurate than any other partial combination of scales. Of note, we included the earliest manuscripts with fully described methods and comprising two, then three and
then four or more genomics scales for each of the three prediction types: (i) diagnosis, (ii) prognosis, (iii) therapeutic response.
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of genomic studies, very few biomarkers have been discovered for
complex disorders in the last decade. Breaking from the biomarker
tradition, classiﬁers consisting of multiple molecular features have
been accurately designed from single ‘omics scales to predict
clinical outcome. Multiscale genomic predictors have in theory
the potential to surpass single scale ones, which have been demon-
strated in practice through signiﬁcant increase of sensitivity while
maintaining the same level of speciﬁcity [6].
As shown in Fig. 1, studies of cross-scale (2-scales) corrobora-
tions of classiﬁers of clinical outcome (Fig. 1, triangles) have ﬁrst
been designed for diagnoses (Golub’s team; 2005) [8], prognosis
(Huang’s team; 2002) [9] and recently addressed response to ther-
apy (Nephew’s team; 2009) [10]. Three cross-scale studies pio-
neered data fusion in each category of clinical predictions: (i)
Shen et al. used joint latent variable for cancer diagnosis (2009;
copy number variation, gene expression) [11], Stuart’s team im-
puted pathway scores from copy number variation and gene
expression for cancer prognosis (2010) [12] and (iii) Daemen
et al. fused microarray and proteomics/genomics data into the ker-
nel of support vector machine and predicted response to therapy
(2009) [13].
Miska’s pioneered multiscale corroborative methods for clinical
classiﬁcation (miRNA, mRNA, CNV) [14], while Johnson’s team was
ﬁrst to utilize them across four genomic scales (copy number var-
iation, mRNA, microRNA and methylation) [15]. Sander’s team pio-
neered the multiscale data fusion to predict time-to-recurrence of
serous ovarian tumors (2011) [16]. They integrated four scales
with Cox Lasso models (mRNA, microRNA, methylation and copy
number variation). They were followed by several other multiscale
data fusion models that built from The Cancer Genome Atlas(TCGA) datasets [17] (e.g. matrix factorization techniques [18],
integrated pathway scores [19,20], and mutual exclusivity [20,21]).
Kim et al. classiﬁes clinical prognosis by fusing four ‘omics
scales: mRNA expression, microRNA expression, copy number var-
iation (CNV), and DNA methylation [7]. While graph-based semi-
supervised learning (SSL) [22] was previously used for clinical out-
come analysis with a single genomic scale [23], Kim’s team initiate
its application using multiple scales. They employ a minimum
objective function integrating two factors from each ‘omics data-
set: (i) regression errors for all patients (loss function) and (ii) con-
cordance between class similarity and their underlying feature
similarity for every pair of patients (smoothness). The clinical clas-
siﬁer Kim et al. developed leverages multiscale ‘omics data fusion
and demonstrates more accuracy than using each of the four single
‘omics scale separately or any combinations (10 combinations tak-
ing 2 or 3 scales at a time). Previous studies were not as systematic
and overlooked the lower order combinations. The algorithm also
advances computational efﬁciency due to the impressive use of
several straightforward matrix operations, an approach not re-
quired when used in single scales by previous authors. Additional
predictive power can probably be obtained by modeling, in more
detail, some of the ‘omics interactions rather than using a single
approach to the integration. Further, these approaches should be
conﬁrmed in prospective independent studies. SSL should be ap-
plied to therapeutic response prediction problems that remain a
greater challenge than prognostic.
While the commercial application of omics classiﬁers will re-
quire cost-efﬁcient solutions, a tradeoff is likely to occur between
the number of omics scales and the accuracy of clinical decision
making. With their comprehensive analysis of the accuracy of
every combination of scales, Kim et al. provide a systematic
Y.A. Lussier, H. Li / Journal of Biomedical Informatics 45 (2012) 1199–1201 1201approach to the optimization of accuracy vs costs. Whether multi-
scale classiﬁers can provide sufﬁcient increase in clinical utility to
justify their costs remains to be established and a domain of active
research (e.g. NIH/NCI PAR-11-151 SPEC II grants funding clinical
trials in multi-analytes signatures).Funding
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